Efficacy and Safety of Sacubitril and Valsartan in the Treatment of Patients with Chronic Heart Failure and Type 2 Diabetes Mellitus:A Meta-Analysis
Objective To systematically evaluate the efficacy and safety of sacubitril and valsartan in the treatment of patients with chronic heart failure(CHF)complicated with type 2 diabetes mellitus(T2DM).Methods The randomized controlled trials(RCTs)of sacubitril and valsartan in the treatment of CHF complicated with T2DM in the PubMed,Embase,Web of Science,The Cochrane Library,CNKI,Wanfang,VIP,and SinoMed databases were searched from January 1990 to February 2023.The Cochrane Systematic Review guidelines(Version 5.1.0)were used for bias risk assessment,the modified Jadad scale was used for quality evaluation of the included literature,and RevMan 5.3 software was used to perform the Meta-analysis.Results A total of 11 RCTs were included,involving 7 075 patients,including 3 569 cases in the test group and 3 506 cases in the control group.The Meta-analysis results showed that the improvement of the clinical efficacy[OR=1.94,95％CI(1.20,3.12),P=0.007],left ventricular ejection fraction[MD=6.67,95％CI(4.87,8.47),P＜0.000 01],N-terminal pro-brain natriuretic peptide[MD=-621.60,95％CI(-813.81,-429.38),P＜0.000 01],glycosylated hemoglobin[MD=-0.41,95％CI(-0.73,-0.09),P=0.01],fasting blood glucose[MD=-1.03,95％CI(-1.62,-0.45),P=0.000 5]in the test group was significantly better than that in the control group.The incidence of adverse drug reactions in the test group was significantly lower than that in the control group[OR=0.59,95％CI(0.38,0.93),P=0.02].Conclusion Sacubitril and valsartan have good efficacy in the treatment of CHF complicated with T2DM has good efficacy and safety,which can improve patients'cardiac function indexes and reduce the level of glycosylated hemoglobin and fasting blood glucose.
sacubitril and valsartanchronic heart failuretype 2 diabetes mellitusefficacysafetyMeta-analysis
万方数据
维普
